Company intelligence / Profile preview

RheaVita

Ghent, Flanders, Belgium

Ownership: Private
Employees: ~16
Development stage: Other

Overview

RheaVita has not reported proprietary clinical results; rather, it enables pharmaceutical and biotechnology clients to accelerate lyophilized product development and commercialization through its continuous freeze-drying platform for high-value biologics[3][4][5][7].

Modalities: mRNA-based drugsViral vectorsMonoclonal antibodyAntibody-drug conjugateVaccine
Industry: Contract Manufacturing Organization

Partnerships

IMA Life (strategic partnership for technology and global commercialization, includes investment and manufacturing collaboration)

Beyond the preview

Go deeper on RheaVita.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RheaVita.

Explore the full profile